CEACAM5 and familial pancreatic carcinoma: Hu et al. reported the benefit of anti-CEA (antibody against the carcinoembryonic antigen, a protein present in certain cancers)-conjugated PLHNPs against 90% of CEA-overexpressing pancreatic cancers.